High Pointe Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

High Pointe Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$3.23M	Sell	44,277 -6,470	-13%	-$434K	2.32%	10
2021 Q4	$3.16M	Buy	50,747 +9,744	+24%	+$572K	2.11%	8
2021 Q3	$2.43M	Hold	41,003	–	–	1.92%	12
2021 Q2	$2.74M	Sell	41,003 -506	-1%	-$33K	2.16%	7
2021 Q1	$2.62M	Buy	41,509 +200	+0.5%	+$12.4K	2.3%	8
2020 Q4	$2.56M	Buy	41,309 +6,133	+17%	+$377K	2.43%	8
2020 Q3	$2.12M	Sell	35,176 -7,610	-18%	-$458K	2.57%	6
2020 Q2	$2.52M	Sell	42,786 -1,690	-4%	-$101K	3.31%	3
2020 Q1	$2.48M	Sell	44,476 -550	-1%	-$33.6K	3.53%	3
2019 Q4	$2.89M	Buy	45,026 +1,730	+4%	+$99.1K	3.43%	4
2019 Q3	$2.2M	Sell	43,296 -3,360	-7%	-$158K	3%	5
2019 Q2	$2.12M	Buy	46,656 +17,340	+59%	+$808K	2.96%	5
2019 Q1	$1.4M	Sell	29,316 -370	-1%	-$18.4K	1.91%	13
2018 Q4	$1.54M	Buy	29,686 +3,220	+12%	+$173K	2.54%	9
2018 Q3	$1.64M	Hold	26,466	–	–	2.21%	11
2018 Q2	$1.47M	Sell	26,466 -140	-0.5%	-$7.56K	2.09%	15
2018 Q1	$1.68M	Sell	26,606 -600	-2%	-$38.6K	2.31%	6
2017 Q4	$1.67M	Buy	27,206 +366	+1%	+$22.9K	2.27%	9
2017 Q3	$1.71M	Buy	26,840 +140	+0.5%	+$8.18K	2.5%	7
2017 Q2	$1.49M	Buy	26,700 +11,390	+74%	+$620K	2.31%	10
2017 Q1	$833K	Buy	+15,310	New	+$840K	1.32%	32
2016 Q3	–	Sell	-13,193	Closed	-$970K	–	78
2016 Q2	$970K	Hold	13,193	–	–	1.48%	28
2016 Q1	$843K	Sell	13,193 -36,950	-74%	-$2.33M	1.22%	39
2015 Q4	$3.45M	Sell	50,143 -10,620	-17%	-$702K	1.69%	8
2015 Q3	$3.6M	Buy	60,763 +743	+1%	+$47.1K	1.69%	8
2015 Q2	$3.99M	Buy	60,020 +1,980	+3%	+$130K	1.43%	8
2015 Q1	$3.74M	Buy	58,040 +21,850	+60%	+$1.37M	1.34%	9
2014 Q4	$2.14M	Buy	36,190 +7,890	+28%	+$445K	0.94%	36
2014 Q3	$1.45M	Buy	+28,300	New	+$1.41M	0.63%	66

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

High Pointe Capital Management's BMY Position: Q1 2022 in Review

High Pointe Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 13% in Q1 2022, selling an estimated $434K and leaving 44,277 shares worth $3.23M. The position accounts for 2.32% of the portfolio, ranked #10.

High Pointe Capital Management first reported a position in BMY in Q3 2014 and has held it in 29 quarters since. The position peaked at $3.99M in Q2 2015. 2,515 funds tracked by Wall St. Rank hold BMY as of Q1 2022.

High Pointe Capital Management held 44,277 shares of Bristol-Myers Squibb worth $3.23M as of Q1 2022.
High Pointe Capital Management sold 6,470 Bristol-Myers Squibb shares in Q1 2022, an estimated $434K.
Bristol-Myers Squibb made up 2.32% of High Pointe Capital Management's portfolio in Q1 2022, its #10 holding.
High Pointe Capital Management first reported a position in Bristol-Myers Squibb in Q3 2014 and has held it in 29 quarters since.
High Pointe Capital Management's Bristol-Myers Squibb position peaked at $3.99M in Q2 2015.
2,515 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2022.

Based on High Pointe Capital Management's 13F filing for Q1 2022, filed 10 May 2022.